DK2823810T3 - Amfotere liposomer, der omfatter iminolipider - Google Patents
Amfotere liposomer, der omfatter iminolipiderInfo
- Publication number
- DK2823810T3 DK2823810T3 DK14188521.0T DK14188521T DK2823810T3 DK 2823810 T3 DK2823810 T3 DK 2823810T3 DK 14188521 T DK14188521 T DK 14188521T DK 2823810 T3 DK2823810 T3 DK 2823810T3
- Authority
- DK
- Denmark
- Prior art keywords
- iminolipids
- amphoteric liposomes
- amphoteric
- liposomes
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09165106A EP2277508B1 (en) | 2009-07-09 | 2009-07-09 | Emulation of lipoprotein structures |
| EP09171102 | 2009-09-23 | ||
| EP10734065.5A EP2451440B2 (en) | 2009-07-09 | 2010-07-02 | Amphoteric liposomes comprising imino lipids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2823810T3 true DK2823810T3 (da) | 2019-05-27 |
Family
ID=42555953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14188521.0T DK2823810T3 (da) | 2009-07-09 | 2010-07-02 | Amfotere liposomer, der omfatter iminolipider |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20120237589A1 (enExample) |
| EP (2) | EP2451440B2 (enExample) |
| JP (1) | JP5851399B2 (enExample) |
| KR (1) | KR101954912B1 (enExample) |
| CN (2) | CN104744310A (enExample) |
| AU (1) | AU2010270337B2 (enExample) |
| BR (2) | BR112012000255B1 (enExample) |
| CA (1) | CA2765694C (enExample) |
| DK (1) | DK2823810T3 (enExample) |
| ES (1) | ES2527220T5 (enExample) |
| IL (1) | IL216996A0 (enExample) |
| SG (1) | SG177590A1 (enExample) |
| WO (1) | WO2011003834A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2993911T3 (en) | 2008-11-10 | 2025-01-13 | Arbutus Biopharma Corp | Novel lipids and compositions for the delivery of therapeutics |
| CN104744310A (zh) † | 2009-07-09 | 2015-07-01 | 玛瑞纳生物技术有限公司 | 包含亚氨基脂质的两性脂质体 |
| WO2012153338A2 (en) * | 2011-05-12 | 2012-11-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Liposomes comprising polymer-conjugated lipids and related uses |
| CA2838063C (en) * | 2011-06-08 | 2023-07-11 | Shire Human Genetic Therapies, Inc. | Cleavable lipids |
| US10722599B2 (en) | 2015-02-04 | 2020-07-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Lipid assemblies and uses thereof and some pH and electrostatic modulating lipids to be used in said assemblies |
| CN109069654A (zh) * | 2016-03-28 | 2018-12-21 | 富士胶片株式会社 | 制剂、制剂用部件及它们的制造方法 |
| CA3024135C (en) * | 2016-05-16 | 2024-09-24 | Univ Texas | Compositions intended for the administration of RNA in the form of nanoparticles and associated method of use |
| CN110283223B (zh) * | 2018-03-19 | 2022-01-04 | 广州市锐博生物科技有限公司 | 一种阳离子脂质分子及其在核酸递送中的应用 |
| WO2020154594A2 (en) * | 2019-01-25 | 2020-07-30 | Agenovir Corporation | Compositions and methods for treatment of human papillomavirus |
| CN110974954B (zh) * | 2019-12-24 | 2021-03-16 | 珠海丽凡达生物技术有限公司 | 一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法 |
| CN113546177A (zh) * | 2021-07-15 | 2021-10-26 | 郑州大学 | 一种胆固醇单胍偶联物及其制备方法和应用 |
| WO2024160829A1 (en) | 2023-01-31 | 2024-08-08 | BioNTech SE | Compositions and methods |
| CN116370437A (zh) * | 2023-05-26 | 2023-07-04 | 北京因诺惟康医药科技有限公司 | 包含胆固醇琥珀酸单酯的核酸脂质纳米颗粒组合物及其用途 |
| WO2025093665A1 (en) | 2023-10-31 | 2025-05-08 | BioNTech SE | Particles, compositions and methods |
| WO2025176732A1 (en) | 2024-02-20 | 2025-08-28 | BioNTech SE | Compositions and methods |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| AU6045094A (en) | 1993-02-19 | 1994-09-14 | Nippon Shinyaku Co. Ltd. | Drug composition containing nucleic acid copolymer |
| US5651981A (en) | 1994-03-29 | 1997-07-29 | Northwestern University | Cationic phospholipids for transfection |
| US5777153A (en) * | 1994-07-08 | 1998-07-07 | Gilead Sciences, Inc. | Cationic lipids |
| WO1996020208A2 (de) * | 1994-12-28 | 1996-07-04 | Max-Delbrück-Centrum für Molekulare Medizin | Neues cholesterolderivat für den liposomalen gentransfer |
| US5965434A (en) | 1994-12-29 | 1999-10-12 | Wolff; Jon A. | Amphipathic PH sensitive compounds and delivery systems for delivering biologically active compounds |
| US6726894B1 (en) | 1995-07-25 | 2004-04-27 | Synvolux Ip B.V. | Transport vehicles for macromolecules |
| US5980935A (en) | 1996-05-15 | 1999-11-09 | Kirpotin; Dmitri | Cationic lipids and methods of use therefor |
| DE19631189A1 (de) | 1996-08-02 | 1998-02-05 | Max Delbrueck Centrum | Neuartige kationische Amphiphile für den liposomalen Gentransfer |
| CA2217550A1 (en) * | 1996-10-22 | 1998-04-22 | F. Hoffmann-La Roche Ag | Cationic lipids for gene therapy |
| DE19648625A1 (de) | 1996-11-13 | 1998-05-14 | Soft Gene Gmbh | Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer |
| DE69841002D1 (de) | 1997-05-14 | 2009-09-03 | Univ British Columbia | Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln |
| DE19753182A1 (de) | 1997-11-21 | 1999-07-29 | Claas Junghans | Topologisch fixierte matrixgebundene Nukleinsäure |
| DE19753132C5 (de) | 1997-11-29 | 2010-05-20 | Geze Gmbh | Brandschutzschiebetüranlage |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6171862B1 (en) * | 1998-03-31 | 2001-01-09 | The Regents Of The University Of California | Transfection in serum-containing media |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| EP1252137A1 (en) | 2000-01-28 | 2002-10-30 | The Procter & Gamble Company | Palatable arginine compounds and uses thereof for cardiovascular health |
| DE10109897A1 (de) † | 2001-02-21 | 2002-11-07 | Novosom Ag | Fakultativ kationische Liposomen und Verwendung dieser |
| MXPA03008864A (es) * | 2001-03-26 | 2004-12-06 | Johnson & Johnson | Composicion de liposoma para el suministro intracelular mejorado en un agente terapeutico. |
| ES2340532T3 (es) | 2001-06-05 | 2010-06-04 | Curevac Gmbh | Arnm con un contenido g/c aumentado que codifica para un antigeno bacteriano y utilizacion del mismo. |
| TWI257924B (en) * | 2003-09-22 | 2006-07-11 | Lipotek Inc | Cationic lipid for delivery function, and nanoparticle comprising the same |
| JP2007091657A (ja) * | 2005-09-29 | 2007-04-12 | Terumo Corp | アミジン誘導体およびそれを構成成分とする薬物担体 |
| JP5122474B2 (ja) * | 2005-12-01 | 2013-01-16 | プロネイ・セラピューティクス・インコーポレイテッド | 両性リポソーム製剤 |
| EP2004141A2 (en) | 2006-03-17 | 2008-12-24 | Novosom AG | An efficient method for loading amphoteric liposomes with nucleic acid active substances |
| EP2462924A3 (en) * | 2006-10-13 | 2013-01-23 | Marina Biotech, Inc. | Improvements in or relating to amphoteric liposomes. |
| AU2008247488B2 (en) * | 2007-05-04 | 2014-02-27 | Marina Biotech, Inc. | Amino acid lipids and uses thereof |
| DE102007029471A1 (de) * | 2007-06-20 | 2008-12-24 | Novosom Ag | Neue fakultativ kationische Sterole |
| WO2009031896A2 (en) * | 2007-09-07 | 2009-03-12 | Synvolux Ip B.V. | Improved liposomes and uses thereof |
| CA2702103A1 (en) | 2007-10-12 | 2009-04-16 | Novosom Ag | Improvements in or relating to amphotaric liposomes comprising neutral lipids |
| JP5749494B2 (ja) | 2008-01-02 | 2015-07-15 | テクミラ ファーマシューティカルズ コーポレイション | 核酸の送達のための改善された組成物および方法 |
| ES2816639T3 (es) | 2008-03-18 | 2021-04-05 | Mk Systems Usa Inc | Un servidor VOD de velocidad controlada |
| MX2010012326A (es) | 2008-05-19 | 2010-12-01 | Univ North Carolina | Metodos y composiciones que comprenden nuevos lipidos cationicos. |
| CN104744310A (zh) † | 2009-07-09 | 2015-07-01 | 玛瑞纳生物技术有限公司 | 包含亚氨基脂质的两性脂质体 |
-
2010
- 2010-07-02 CN CN201510053094.3A patent/CN104744310A/zh active Pending
- 2010-07-02 SG SG2012001673A patent/SG177590A1/en unknown
- 2010-07-02 BR BR112012000255-4A patent/BR112012000255B1/pt active IP Right Grant
- 2010-07-02 US US13/378,484 patent/US20120237589A1/en not_active Abandoned
- 2010-07-02 WO PCT/EP2010/059487 patent/WO2011003834A1/en not_active Ceased
- 2010-07-02 DK DK14188521.0T patent/DK2823810T3/da active
- 2010-07-02 EP EP10734065.5A patent/EP2451440B2/en active Active
- 2010-07-02 ES ES10734065.5T patent/ES2527220T5/es active Active
- 2010-07-02 KR KR1020127003373A patent/KR101954912B1/ko active Active
- 2010-07-02 BR BR212012000255U patent/BR212012000255U2/pt not_active Application Discontinuation
- 2010-07-02 EP EP14188521.0A patent/EP2823810B9/en active Active
- 2010-07-02 CN CN201080031041.7A patent/CN102481256B/zh active Active
- 2010-07-02 JP JP2012518924A patent/JP5851399B2/ja active Active
- 2010-07-02 CA CA2765694A patent/CA2765694C/en active Active
- 2010-07-02 AU AU2010270337A patent/AU2010270337B2/en active Active
-
2011
- 2011-12-15 IL IL216996A patent/IL216996A0/en unknown
-
2016
- 2016-02-22 US US15/050,416 patent/US10039714B2/en active Active
-
2018
- 2018-08-01 US US16/051,728 patent/US20180338919A1/en not_active Abandoned
-
2020
- 2020-05-04 US US16/866,363 patent/US11541010B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP5851399B2 (ja) | 2016-02-03 |
| CA2765694A1 (en) | 2011-01-13 |
| AU2010270337A1 (en) | 2012-02-23 |
| CN104744310A (zh) | 2015-07-01 |
| CA2765694C (en) | 2021-05-18 |
| WO2011003834A1 (en) | 2011-01-13 |
| US20180338919A1 (en) | 2018-11-29 |
| EP2451440A1 (en) | 2012-05-16 |
| EP2451440B1 (en) | 2014-11-12 |
| KR20120046737A (ko) | 2012-05-10 |
| IL216996A0 (en) | 2012-02-29 |
| JP2012532839A (ja) | 2012-12-20 |
| BR112012000255A2 (enExample) | 2015-11-03 |
| EP2823810B9 (en) | 2019-10-30 |
| US10039714B2 (en) | 2018-08-07 |
| EP2823810A1 (en) | 2015-01-14 |
| EP2823810B1 (en) | 2019-03-27 |
| ES2527220T5 (es) | 2018-06-05 |
| AU2010270337B2 (en) | 2016-09-22 |
| ES2527220T3 (es) | 2015-01-21 |
| KR101954912B1 (ko) | 2019-03-08 |
| CN102481256B (zh) | 2015-02-25 |
| SG177590A1 (en) | 2012-03-29 |
| US20200330384A1 (en) | 2020-10-22 |
| CN102481256A (zh) | 2012-05-30 |
| US20160338957A1 (en) | 2016-11-24 |
| BR112012000255B1 (pt) | 2022-11-29 |
| US20120237589A1 (en) | 2012-09-20 |
| US11541010B2 (en) | 2023-01-03 |
| BR212012000255U2 (pt) | 2015-11-03 |
| EP2451440B2 (en) | 2018-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2823810T3 (da) | Amfotere liposomer, der omfatter iminolipider | |
| DK2414015T3 (da) | Laryngoskopsystem | |
| DK2411442T4 (da) | Umættet polyesterresin | |
| DE112010004215A5 (de) | Hydrostataktor | |
| DE112010002949A5 (de) | Kupplungstastpunkte | |
| DK2430035T3 (da) | Uracylspipooxetannukleosider | |
| BRPI1008827A2 (pt) | deisobutenizador | |
| BR112012000657A2 (pt) | novos azabicilohexanos | |
| UY33125A (es) | Diaza-espiro-[5,5]-undecanos | |
| BRPI1014968A2 (pt) | subalargador | |
| DE112010002728A5 (de) | Turboinhalator | |
| ATE546999T1 (de) | Feldspritze | |
| DE112010004249A5 (de) | Spindelaktor | |
| DE112009005323A5 (de) | Hebelarmprüfmaschine | |
| DE112009005462T8 (de) | Lenkungsssteuervorrichtung | |
| BR112012004964A2 (pt) | girocóptero | |
| BRPI1008070A2 (pt) | tricianoboratos | |
| DK2483126T3 (da) | Skinnekøretøj | |
| DE112010004865T8 (de) | Lamellennassreibkupplung | |
| DK2506968T3 (da) | Faujasit-zeolit | |
| EP2380788A4 (en) | SAFETY BELT RETRACTOR | |
| DE112010003255A5 (de) | Fördergutverteiler | |
| BRPI1010159A2 (pt) | bistuti | |
| ES1070429Y (es) | Traspaleta mejorada | |
| DE602010000025D1 (de) | Fahrzeugsitzgurtvorrichtung |